Meta-analysiscited by the Tayebat archivefull text checked★ key study A-SOD-01 in-depth review
Sugary drinks and diabetes risk: pooled cohorts
Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis.
Overview
Malik VS et al.. Diabetes Care 2010 · PMID 20693348 · DOI 10.2337/dc10-1079
People in the highest intake group had a 26% higher risk of type 2 diabetes than those drinking almost none.
Does the study support the specific claim? Yes · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Is SSB intake associated with incident metabolic syndrome and type 2 diabetes?
- How was the study done?
Systematic search (MEDLINE to May 2010) and random-effects meta-analysis of prospective cohorts, highest vs lowest SSB quantile.
- How many people, animals or samples were studied?
11 cohorts; 310,819 participants; 15,043 T2D cases; 19,431 participants/5,803 cases for metabolic syndrome; Adults in prospective cohorts
- What was actually found?
T2D: RR 1.26 (95% CI 1.12-1.41); metabolic syndrome: RR 1.20 (1.02-1.42).
- How large was the observed effect?
RR 1.26 (1.12-1.41)
- What do the results mean in everyday life?
Regular sugary drinks are linked with more diabetes.
- What are the study's limitations?
Only MEDLINE; no risk-of-bias assessment; high heterogeneity; observational studies; overlaps with later meta-analyses
- What does it say about Elawady's specific claim?
Core evidence for C-SOD-01.
- Do the results apply to Germany and Europe?
High; cohorts from Western populations.
- What can explicitly not be concluded from this study?
That sugary drinks alone cause the difference.
Scientific in-depth review
1. Full reference
- Authors
- Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB
- Journal
- Diabetes Care
- Year
- 2010
- Identifier
- PMID 20693348 DOI 10.2337/dc10-1079 · PMC2963518
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
No potential conflicts of interest reported. No funding statement in the full-text file.
2. Research question
Is SSB intake associated with incident metabolic syndrome and type 2 diabetes?
3. Study design and population
- Study design
- Meta-analysis – Systematic search (MEDLINE 1966 - May 2010, English) and random-effects meta-analysis of prospective cohorts, extreme quantiles plus dose-response; no registered protocol
- Population
Adults in prospective cohorts
- Country
USA (7 of 9 T2D data points incl. NHS, NHS II, HPFS, BWHS, ARIC, MESA), Finland, Singapore
- Period
Literature 1966 - May 2010; cohort follow-up 4-20 years
- Sample size
11 studies: 8 studies (9 data points) for T2D with 310,819 participants and 15,043 cases; 3 studies for metabolic syndrome with 19,431 participants and 5,803 cases
- Inclusion and exclusion criteria
Prospective cohorts in adults reporting RR with variance, SSB definition and confounder adjustment; cross-sectional and short-term experimental studies excluded; one unpublished study (HPFS) by personal communication
4. Methods and endpoints
- Exposure / intervention
SSB intake, highest quantile (most often >=1-2 servings/day; exceptions e.g. >=2 servings/week in Singapore, 143 g/day in Finland)
- Comparator
Lowest quantile (none or <1 serving/month)
- Endpoints
Incident type 2 diabetes; metabolic syndrome
- Statistical methods
DerSimonian-Laird random effects (fixed effects as sensitivity); Q test and I2; meta-regression on energy adjustment and duration; Begg/Egger tests; dose-response per 12-oz serving/day; sensitivity excluding energy/adiposity-adjusted estimates
5. Actual results
- Results
T2D highest vs lowest: RR 1.26 (95% CI 1.12-1.41), I2 66% (31-83%); fixed effects 1.25 (1.17-1.32). Dose-response per 1 serving/day: RR 1.25 (1.10-1.42) random, 1.15 (1.11-1.20) fixed. Excluding energy/adiposity-adjusted estimates: RR 1.28 (1.13-1.45); dose-response 1.35 (1.14-1.59). Metabolic syndrome: RR 1.20 (1.02-1.42), I2 76%; fixed 1.17 (1.09-1.26); the two adiposity-adjusted studies were marginal/non-significant, the strongest (Dhingra, RR 1.39) adjusted only for age and sex and included diet soft drinks. All T2D studies except MESA (RR 0.86) were positive. Begg P=0.75, Egger P=0.75 (T2D): no evidence of publication bias.
- Absolute risks
not reported in full text
- Authors' conclusion
Higher consumption of SSBs is associated with development of metabolic syndrome and type 2 diabetes; intake should be limited.
6. Strengths
- Prospective cohorts only; mostly validated FFQs
- Dose-response and sensitivity analyses for mediator adjustment
- Duplicate data extraction; unpublished estimates obtained
- Publication bias assessed
7. Weaknesses
- Only MEDLINE, English only; no protocol registration
- No formal risk-of-bias assessment of cohorts
- Substantial heterogeneity (I2 66% T2D, 76% metabolic syndrome)
- Non-standardised extreme categories
- Residual confounding by overall unhealthy diet and reverse causation acknowledged by authors
- Metabolic syndrome estimate based on 3 studies, one including diet soft drinks with only age/sex adjustment
- Overlaps with later meta-analyses (A-SOD-08, A-SOD-23); same research group as several included cohorts
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- high
- Rationale
Changed from some_concerns: several critical AMSTAR 2 weaknesses (no protocol, single-database search, no excluded-study list, no risk-of-bias assessment) mean confidence would be rated 'critically low' by AMSTAR 2, even though the pooled estimate has been confirmed by later, more rigorous meta-analyses (A-SOD-08). Structured single-reviewer judgement from full text; a formal assessment would require two independent reviewers and a protocol.
| Domain | Judgement | Rationale |
|---|---|---|
| Item 2 protocol registered (critical) | high | No protocol or registration reported. |
| Item 4 comprehensive search (critical) | high | MEDLINE only, English; one study by personal communication. |
| Item 5/6 duplicate selection/extraction | some concerns | Duplicate extraction by two authors; selection process not described as duplicate. |
| Item 7 excluded studies justified (critical) | high | No list of excluded studies. |
| Item 9 risk of bias of included studies (critical) | high | No formal RoB/quality assessment; confounder sets tabulated only. |
| Item 11 appropriate meta-analytic methods (critical) | low | Random effects with heterogeneity assessment, dose-response and sensitivity analyses. |
| Item 13 RoB considered in interpretation (critical) | some concerns | Residual confounding and reverse causation discussed, but conclusions phrased strongly ('clear link'). |
| Item 15 publication bias (critical) | low | Funnel plot, Begg and Egger tests. |
| Item 16 COI | low | No conflicts reported. |
Full-text review (25 October 2026): Added per-study table details, heterogeneity (I2 66%/76%), fixed-effect and dose-response estimates (per serving RR 1.25/1.15), sensitivity excluding adjusted estimates (1.28; 1.35), publication-bias tests, metabolic-syndrome caveats; AMSTAR 2 items added; bias changed some_concerns -> high.
9. Assessment of the statistical interpretation
Consistent moderate relative association (about 25% higher T2D risk per daily serving or for highest vs lowest intake) with substantial heterogeneity; partly mediated by adiposity (excluding adjusted estimates strengthened it). Absolute risk not reported. The 'each daily serving about 18%' figure in the claim is not from this paper (here per-serving RR 1.25 random / 1.15 fixed).
10. Relevance to the specific claim
Core evidence for C-SOD-01.
11. Independent contrary findings
No contradicting meta-analysis found; later analyses confirm direction (A-SOD-08, A-SOD-23).
12. Transferability to Germany and Europe
High; cohorts from Western populations.
13. Overall methodological judgement
Reliable summary of early cohort evidence; superseded by larger dose-response analyses.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | high |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | essentially correct but incomplete |
14. Open questions
Causal effect size.
15. Linked fact checks
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Meta-analysis of 11 cohorts: one to two sugary sodas per day raised type 2 diabetes risk by 26% and metabolic syndrome risk by 20%.
- A. What was actually studied?
Pooled prospective associations of SSB intake with T2D and metabolic syndrome.
- B. What did the authors find?
RR 1.26 (T2D) and 1.20 (metabolic syndrome) highest vs lowest quantile.
- C. What conclusions do the authors themselves draw?
SSB intake is associated with these diseases and should be limited.
- D. What does the archive derive from it?
Presents the association as a causal 'raise' in risk.
- E. Is this derivation scientifically justified?
Numbers correct (RR 1.26 and 1.20); 'raised' implies causation that an observational meta-analysis cannot establish, though consistent with the authors' public-health message. The per-serving estimate in this paper is RR 1.25 (random) / 1.15 (fixed), not 18%; the metabolic-syndrome estimate is weak (3 studies, one including diet drinks).
- Adequacy of the interpretation (by the archive)
- essentially correct but incomplete